345 PARK AVENUE SOUTH, NEW YORK, NY
Announces Pricing of Public Offering and Concurrent Private Placement
Investor Presentation
Reports Second Quarter 2025 Financial Results and Operational Highlights
Shareholder votes
Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Reports First Quarter 2025 Financial Results and Operational Highlights
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Q2
Amended Quarterly Report
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus